Award Year
2021
Award Type
Targeted: Genomics of ASD: Pathways to Genetic Therapies
Awardees
Samouil Farhi
SFARI Investigator
Ralda Nehme
SFARI Investigator
Bringing people and ideas together to fund, conduct, and share transformative science.
Our grants advance knowledge and strengthen connections between science and society.
Discover the latest news, research, and updates.
We convene scientists, mathematicians, and thinkers to share ideas and explore new questions.
Founded by Jim and Marilyn Simons, we’re a private philanthropy advancing mathematics and basic science.
Work with us on the frontier of basic science research.
The Flatiron Institute is a research center that uses computational science to advance fields like physics, biology, and astronomy.
Search
Funded Work
2021
Targeted: Genomics of ASD: Pathways to Genetic Therapies
SFARI Investigator
SFARI Investigator
While genetic studies have identified numerous risk variants and genes for autism spectrum disorder (ASD), therapeutic development requires both better understanding of the genes’ neurobiological roles and scalable assays to identify potential chemical or genetic interventions. This challenge is especially daunting given the large number of ASD risk genes found to date — at present there are 207 high-confidence SPARK genes including 50 prioritized by SFARI for their translational potential, with even more likely to come. Tackling this list piecemeal with traditional techniques will be prohibitively time consuming, and new, highly parallel discovery approaches are required.
Meanwhile, emerging lines of evidence show that fingerprinting of cells — defined here as measurements which parameterize cell state among hundreds to thousands of separate features — not only can offer insight about the phenotypic consequences of a genetic perturbation but also can cluster genetic or chemical perturbations by likely common mechanisms of action. Fingerprinting assays typically scale well, in principle simplifying the transition from neurobiological discovery to assay development.
Samouil Farhi and Ralda Nehme’s laboratories have developed a rich assay palette for transcriptomic, morphological and electrophysiological fingerprinting pooled cultures of human neurons derived from induced pluripotent stem cells. In this project, their teams will leverage these assays to perform pooled knockdown screens of high-confidence ASD risk genes, identifying modulated features and gaining insight into the neurobiological roles of the genes. They will then use the same assays in large case-control pools harboring ASD risk variants in the same genes to identify features linked to gene rather than genetic background and confirm this by correcting the relevant mutation. The overall approach will both provide information about the roles of genes, enable clustering of genes by potential common roles and guide the development of highly scalable therapeutic discovery assays.